Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients.

Authors:
Humza N Mirza Fatima N Mirza Khalil A Khatri

Dermatol Ther 2021 01 2;34(1):e14432. Epub 2020 Nov 2.

Skin & Laser Surgery Center of New England, Nashua, New Hampshire, USA.

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA-compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms "ablative laser" and "skin resurfacing" from March 2002 until July 2020. Studies included meta-analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self-resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.14432DOI Listing
January 2021

Publication Analysis

Top Keywords

adverse events
16
systematic review
16
skin resurfacing
16
ablative laser
12
nonablative lasers
12
ablative lasers
8
laser skin
8
compared nonablative
8
events compared
8
events
8
safe effective
8
lasers skin
8
effective modality
8
1093 patients
8
modality treat
8
ablative
7
studies
5
lasers
5
skin
5
studies included
4

Keyword Occurance

Similar Publications

Adherence, persistence and switching rates of apixaban, dabigatran and rivaroxaban in non-valvular atrial fibrillation: a multicentre real-life analysis at 3 years.

Authors:
Alessia Romagnoli Fiorenzo Santoleri Alberto Costantini Angelora Di Risio

Eur J Hosp Pharm 2022 Aug 12. Epub 2022 Aug 12.

Territorial Pharmaceutical Service, Local Health Unit Lanciano Vasto Chieti, Chieti, Italy.

Introduction: Adherence to and persistence with long-term treatment with oral anticoagulants play a significant role in preventing adverse events and mortality in patients with cardiac conditions. The aim of this study was to evaluate the adherence, persistence and switching rate at 3 years in real-life patients with non-valvular atrial fibrillation receiving treatment with first-line new oral anticoagulants.

Methods: The study assessed all patients treated with drugs with the ATC codes B01AA, B01AE, B01AF and dispensed in pharmacies in the Lanciano-Vasto-Chieti and Pescara Local Health Units from 1 January 2011 to 30 September 2021. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.

Authors:
Hermine I Brunner Ivan Foeldvari Ekaterina Alexeeva Nuray Aktay Ayaz Inmaculada Calvo Penades Ozgur Kasapcopur Vyacheslav G Chasnyk Markus Hufnagel Zbigniew Żuber Grant Schulert Seza Ozen Adelina Rakhimyanova Athimalaipet Ramanan Christiaan Scott Betul Sozeri Elena Zholobova Ruvie Martin Xuan Zhu Sarah Whelan Luminita Pricop Alberto Martini Daniel Lovell Nicolino Ruperto

Ann Rheum Dis 2022 Aug 12. Epub 2022 Aug 12.

IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy.

Background: Treatment options in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) are currently limited. This trial aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA with inadequate response to conventional therapy.

Methods: In this randomised, double-blind, placebo-controlled, treatment-withdrawal, phase 3 trial, biologic-naïve patients (aged 2 to <18 years) with active disease were treated with open-label subcutaneous secukinumab (75/150 mg in patients <50/≥50 kg) in treatment period (TP) 1 up to week 12, and juvenile idiopathic arthritis (JIA) American College of Rheumatology 30 responders at week 12 were randomised 1:1 to secukinumab or placebo up to 100 weeks. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis.

Authors:
Muhammad Usman Ali G B John Mancini Donna Fitzpatrick-Lewis Ruth Lewis Milos Jovkovic Shelley Zieroth Eileen O'Meara Kim A Connelly Diana Sherifali

Can J Cardiol 2022 Aug;38(8):1201-1210

School of Nursing, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada. Electronic address:

Background: Evidence for the cardiorenal risk reduction properties of antihyperglycemic medications originally prescribed for type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) is rapidly emerging. We completed a meta-analysis of recent literature to provide evidence-based estimates of benefit across various populations and outcomes.

Methods: We searched Medline and Cochrane databases from 2015 to September 2021 for randomized controlled trials of SGLT2i and GLP-1RA with placebo control. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Safety and Tolerability of mRNA COVID-19 Vaccines in Kidney Transplant Recipients.

Authors:
Zuzanna Ślizień Marta Muchlado Alicja Kubanek Bogdan Biedunkiewicz Marcin Renke Karolina Komorowska Alicja Dębska-Ślizień Leszek Tylicki

Transplant Proc 2022 May 17;54(4):878-883. Epub 2022 Mar 17.

Department of Nephrology, Transplantology and Internal Medicine; Medical University of Gdańsk. Electronic address:

Background: COVID-19 mRNA vaccines have demonstrated excellent short-term safety in phase 3 trials. However, no kidney transplant recipients (KTR) were included. The aim of the study was to assess the safety and tolerability of COVID-19 mRNA vaccines in KTR. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'target trial'.

Authors:
Maria Pufulete Jessica Harris Koen Pouwels Barney C Reeves Daniel Lasserson Yoon K Loke Andrew Mumford Kalaivani Mahadevan Thomas W Johnson

Open Heart 2022 Aug;9(2)

School of Cellular and Molecular Medicine, Bristol Medical School, University of Bristol, Bristol, UK.

Objective: To estimate the incidence and HRs for bleeding for different dual antiplatelet therapies (DAPT) in a real-world population with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) in England.

Design: A retrospective, population-based cohort study emulating a target randomised controlled trial (tRCT).

Data Sources: Linked Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES). Read More

View Article and Full-Text PDF
August 2022
Similar Publications
}
© 2022 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap